Regeneron has a long history with its gene-sequencing efforts, which likely provides some hints as to why the biotech saw the ...

Boehringer Ingelheim claimed two Phase 3 wins for its PDE4 inhibitor in fibrotic lung diseases, but some Wall Street analysts said the candidate’s “modest” efficacy and limited combination potential ...

Prime Medicine announced Monday morning what it called 'breakthrough' clinical results from the first patient who received ...

Intellia's CRISPR therapy nexiguran ziclumeran maintained reductions in the levels of a misfolded protein in the nerves of ...

Scientists led by David Liu and Samuel Sternberg develop improved CRISPR-based gene insertion tool called evoCAST, boosting ...

Regeneron is acquiring 23andMe through a court-supervised sale, following 23andMe's bankruptcy filing and recent struggles.

CellCentric raises $120M Series C for p300/CBP inhibitor inobrodib in multiple myeloma, plans Phase 2/3 trial for accelerated ...